NBSE News and Press, NeuBase Therapeutics Inc. From 12/16/20

NeuBase Therapeutics (NBSE) announces positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1).These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting...

David Einhorn's 13F stock portfolio value increased from $922M to $1.22B this quarter. Greenlight added SYNNEX, NCR, Twitter, Intel, and Ingredion, while reducing AerCap Holdings. The short position in Tesla through puts was increased during the quarter. The largest three position...

SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2020 / Tribe Public announced today that Dietrich Stephan, Ph.D., Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ:NBSE), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, will prese...

PITTSBURGH, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced that Dietrich A. Stephan, ...

22nd Annual H.C. Wainwright Global Investor Conference presentation at  1:30 p.m. ET on September 16 TH Oppenheimer Fall Healthcare LifeSciences & Medtech Summit Fireside Chat at 10:00 a.m. ET on September 23 RD PITTSBURGH, Sept. 08, 2020 (GLOBE NEWSWIRE) -- NeuBase ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 08/14/2020. Please visit our Tracking David Einhorn's Greenlig...

SAN FRANCISCO, CA / ACCESSWIRE / August 24, 2020 / Tribe Public announced today that Dietrich Stephan, Chief Executive Officer of NeuBase Therapeutics, Inc. (NASDAQ:NBSE), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL&#...

NeuBase Therapeutics (NASDAQ: NBSE ) : FQ3 GAAP EPS of -$0.18. More news on: NeuBase Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines Company Continues to Progress Candidates in Huntington’s Disease (HD) and Myotonic Dystrophy (DM1) PITTSBURG...